Bnp And Ntprobnp Market Expected to Reach $3.4 Billion by 2031—Allied Market Research

According to a new report published by Allied Market Research, titled, “Bnp And Ntprobnp Market," The bnp and ntprobnp market size was valued at $1.1 billion in 2021, and is estimated to reach $3.4 billion by 2031, growing at a CAGR of 12.2% from 2022 to 2031. BNP (B-type natriuretic peptide) is produced by the ventricles of the heart in response to increased pressure or volume in the heart and NT-proBNP is a derivative of BNP and is used to diagnose heart failure. Cardiovascular diseases are life-threatening condition that affects millions of people globally with a higher economic burden on the healthcare sector. The early diagnosis of cardiovascular diseases is crucial to improve patient outcomes and reducing the overall cost of care. Therefore, BNP (B-type natriuretic peptide) and NTproBNP (N-terminal pro-B-type natriuretic peptide) are widely used as the most promising biomarkers for diagnosis of various cardiovascular diseases such as myocardial infarction, congestive heart failure (CHF), and others. BNP and NTproBNP are minimally invasive, time-saving, and cost-effective diagnostic tests.

A few reasons for the global BNP and NTproBNP market growth include a rise in the geriatric population more prone to various cardiovascular diseases such as heart failure, stroke, and myocardial infarction, a rise in adoption of BNP and NTproBNP biomarkers for cardiovascular disease diagnosis, and growth in healthcare expenditure are the factors that are expected to boost the market. For instance, according to National Center for Biotechnology Information (NCBI), in 2021, the incidence of heart failure progressively increases with age and is around 20% in people over 75 years old. The rise in a number of geriatric population increases the adoption of BNP and NTproBNP biomarkers, which, in turn, boosts the growth of the BNP and NTprobnp industry. 

Moreover, the rise in awareness of heart failure and the importance of early diagnosis, increase in the utilization of BNP and NTproBNP biomarkers in the diagnosis and management of heart failure further is expected to drive the market growth during the forecast period. For instance, Heart-Health Screening is an awareness program conducted by American Heart Association (AHA), which provides information about various screening tests for cardiovascular disease diagnosis. A rise in awareness about early disease diagnosis further boosts the demand for BNP and NTproBNP biomarkers. Furthermore, there is an increased use of BNP and NTproBNP biomarkers as it provides high sensitivity and specificity in diagnosing heart failure, are cost-effective, compared to other diagnostic tests such as imaging studies and biopsies, and provide the fastest results. Therefore, BNP and NTproBNP biomarkers offer several advantages over other diagnostic tests, which further contribute toward market growth.

However, the BNP and NT-proBNP testing have few adverse effects as these tests may give false-positive results, and limited specificity as the levels of BNP and NTproBNP is not specific for heart disease and can be elevated in other conditions, such as lung disease, liver disease, and renal failure restrain the growth of the market. Furthermore, BNP and NT-proBNP levels can be influenced by a variety of factors, including age, sex, renal function, and certain medications, which can affect test results. All these factors limit the adoption of BNP and NTproBNP biomarkers and negatively impact market growth.

The COVID-19 pandemic had a significant impact on the BNP and NTproBNP market size as many diagnostic testing including those for various cardiovascular diseases by using BNP and NTproBNP biomarkers was delayed or canceled during the pandemic. This measure was taken to keep hospital beds and healthcare providers available for COVID-19 patients which resulted in a decline in demand for BNP and NTproBNP biomarkers and a slowdown in the growth of the market. For instance, according to data published by the Journal of American College of Cardiology, in 2021, the diagnosis rate for heart disease decreased 42% from March 2019 to March 2020, which, in turn, decreased the demand for BNP and NTproBNP. Hence, the BNP and NTproBNP market share is negatively impacted by the COVID-19 pandemic. However, by following COVID-appropriate protocols, diagnosis tests are being carried out, which is expected to provide lucrative growth opportunities in BNP and NTproBNP market share during the forecast period.

On the basis of application, the market is classified into myocardial infarction, congestive heart failure (CHF), acute coronary syndrome (ACS), and others. The myocardial infarction segment was the highest revenue contributor to the market in 2021 and is anticipated to be the fastest-growing segment during the BNP and NTprobnp Market forecast period, owing to a rise in the prevalence of myocardial infarction and increased demand for diagnostic tests, including BNP and NT-proBNP.

On the basis of the location of testing, the BNP and NTprobnp Market Forecast is segmented into point-of-care testing and laboratory testing. The point-of-care testing segment was the highest revenue contributor to the market in the year 2021 and is the fastest-growing segment during the forecast period, owing to the rise in demand for point-of-care testing as it is more convenient as compared to laboratory testing, improve access to care in remote or underserved areas, growing adoption of consumables, and more cost-effective than laboratory testing.

On the basis of region, Asia Pacific has the highest market share in 2021 in BNP and NTprobnp industry, and is expected to maintain its lead during the forecast period, owing to an increase in the availability of BNP and NTproBNP biomarkers; an increase in the adoption of personalized medicine and biomarker-based approaches for the diagnosis and management of heart failure; increase in focus on the development of innovative diagnostic technologies, and increase in awareness about benefits of early disease diagnosis. In addition, Asia-Pacific is expected to exhibit the fastest growth during the forecast period, owing to improvements in the healthcare sector, the surge in the geriatric population that is more vulnerable to cardiovascular diseases, growth in healthcare infrastructure, rise in awareness of heart diseases, and surge in healthcare expenditure.

KEY FINDINGS OF THE STUDY

• Based on application, the myocardial infarction segment held the largest market share in BNP and NTprobnp Market analysis report in 2021 and is expected to remain dominant throughout the forecast period.
• By location of testing, the point-of-care testing segment dominated the global market in 2021 and is anticipated to continue this BNP and NTprobnp Market trends during the forecast period.
• Based on region, Asia-Pacific has dominated the market in 2021 and is expected to register highest CAGR during the forecast period.